Search

Your search keyword '"Zerbini, Cristiano A.F."' showing total 10 results
Start Over Author "Zerbini, Cristiano A.F."
10 results on '"Zerbini, Cristiano A.F."'

3. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Author

Brown, Jacques P., primary, Engelke, Klaus, additional, Keaveny, Tony M., additional, Chines, Arkadi, additional, Chapurlat, Roland, additional, Foldes, A. Joseph, additional, Nogues, Xavier, additional, Civitelli, Roberto, additional, De Villiers, Tobias, additional, Massari, Fabio, additional, Zerbini, Cristiano A.F., additional, Wang, Zhenxun, additional, Oates, Mary K., additional, Recknor, Christopher, additional, and Libanati, Cesar, additional

Published
2021
Full Text
View/download PDF

4. Past and present habitual physical activity and its relationship with bone mineral density in men aged 50 years and older in Brazil

Author

Florindo, Alex A., Latorre, Maria do Rosario D.O., Jaime, Patricia C., Tanaka, Tomoe, Pippa, Maria G.B., and Zerbini, Cristiano A.F.

Subjects
Gerontology -- Research, Exercise -- Physiological aspects, Bones -- Density, Health, Seniors
Abstract

Background. The aim of this study was to determine the relationship between habitual physical activity (HPA) during life and bone mineral density (BMD) in men aged 50 years and older. Methods. A total of 326 men aged 50 years and older, volunteers living in Sao Paulo city, Brazil, were studied. BMD was measured in the whole body, femoral neck, Ward's triangle, trochanter, and lumbar spine (L2-L4) with a dual-energy x-ray absorptiometer. The HPA data were collected with questionnaires inquiring about physical exercise and occupational physical activity in the past and during the past 12 months and leisure and locomotor physical activity in the preceding 12 months. The relationship between BMD and HPA was analyzed using multiple linear regression models adjusted for age and body mass index (BMI). Results. Practice of physical exercise in the past 10-20 years and leisure and locomotor physical activity in the preceding 12 months showed a significant positive correlation with BMD of whole body, femoral neck, trochanter, and lumbar spine, and this association was independent of age and BMI. Conclusions. HPA can contribute to preserving BMD in men aged 50 years and older in Brazil, when it is practiced in the past 10-20 years and even in the present.

Published
2002

5. Maintenance of low disease activity and remission with etanercept–disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Latin American patients with active rheumatoid arthritis

Author

Zerbini, Cristiano A.F., primary, Abud-Mendoza, Carlos, additional, Mendez-Patarroyo, Paul, additional, De Angelo Andrade, Mauricio, additional, Pedersen, Ron, additional, Vlahos, Bonnie, additional, and Borlenghi, Cecilia Elena, additional

Published
2018
Full Text
View/download PDF

6. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies

Author

Charles-Schoeman, Christina, primary, van der Heijde, Désirée, additional, Burmester, Gerd R., additional, Nash, Peter, additional, Zerbini, Cristiano A.F., additional, Connell, Carol A., additional, Fan, Haiyun, additional, Kwok, Kenneth, additional, Bananis, Eustratios, additional, and Fleischmann, Roy, additional

Published
2017
Full Text
View/download PDF

7. Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Author

Cosman, Felicia, primary, Crittenden, Daria B., additional, Adachi, Jonathan D., additional, Binkley, Neil, additional, Czerwinski, Edward, additional, Ferrari, Serge, additional, Hofbauer, Lorenz C., additional, Lau, Edith, additional, Lewiecki, E. Michael, additional, Miyauchi, Akimitsu, additional, Zerbini, Cristiano A.F., additional, Milmont, Cassandra E., additional, Chen, Li, additional, Maddox, Judy, additional, Meisner, Paul D., additional, Libanati, Cesar, additional, and Grauer, Andreas, additional

Published
2016
Full Text
View/download PDF

8. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies

Author

Charles-Schoeman, Christina, van der Heijde, Désirée, Burmester, Gerd R., Nash, Peter, Zerbini, Cristiano A.F., Connell, Carol A., Fan, Haiyun, Kwok, Kenneth, Bananis, Eustratios, and Fleischmann, Roy

Abstract

Objective.Tofacitinib has been investigated for the treatment of rheumatoid arthritis (RA) in phase III studies in which concomitant glucocorticoids (GC) were allowed. We analyzed the effect of GC use on efficacy outcomes in patients with RA receiving tofacitinib and/or methotrexate (MTX) or conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in these studies.Methods.Our posthoc analysis included data from 6 phase III studies (NCT01039688; NCT00814307; NCT00847613; NCT00853385; NCT00856544; NCT00960440). MTX-naive patients or patients with inadequate response to csDMARD or biological DMARD received tofacitinib 5 or 10 mg twice daily alone or with csDMARD, with or without concomitant GC. Patients receiving GC (≤ 10 mg/day prednisone or equivalent) before enrollment maintained a stable dose throughout. Endpoints included the American College of Rheumatology (ACR) 20/50/70 response rates, rates of Clinical Disease Activity Index (CDAI)-defined low disease activity (LDA; CDAI ≤ 10) and remission (CDAI ≤ 2.8), and changes from baseline in CDAI, 28-joint count Disease Activity Score (DAS28-4)–erythrocyte sedimentation rate (ESR), Health Assessment Questionnaire–Disability Index (HAQ-DI), pain visual analog scale (VAS), and modified total Sharp score.Results.Of 3200 tofacitinib-treated patients, 1258 (39.3%) received tofacitinib monotherapy and 1942 (60.7%) received tofacitinib plus csDMARD; 1767 (55.2%) received concomitant GC. ACR20/50/70 response rates, rates of CDAI LDA and remission, and improvements in CDAI, DAS28-4-ESR, HAQ-DI, and pain VAS with tofacitinib were generally similar with or without GC in monotherapy and combination therapy studies. GC use did not appear to affect radiographic progression in tofacitinib-treated MTX-naive patients. MTX plus GC appeared to inhibit radiographic progression to a numerically greater degree than MTX alone.Conclusion.Concomitant use of GC with tofacitinib did not appear to affect clinical or radiographic efficacy. MTX plus GC showed a trend to inhibit radiographic progression to a greater degree than MTX alone.

Published
2018
Full Text
View/download PDF

9. Is It Ethical to Use Placebos in Osteoporosis Trials?

Author

Ragi-Eis, Sergio, primary, Zerbini, Cristiano A.F., additional, Provenza, José R., additional, Griz, Luiz H.M., additional, de Gregório, Luiz H., additional, Russo, Luis A.T., additional, Silva, Nilzio A., additional, Borges, João L.C., additional, de Souza, Antonio C.A., additional, Castro, Marize L., additional, and Lewiecki, E. Michael, additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results